Furocoumarins are one of the most promising agents in the alleviation of oxidative and inflammatory stress-induced pathophysiological morbidities including chronic kidney disease due to their ability to regulate the activity of CASP-3, CASP-8, CASP-9, and SOD. This evidence concerns the gene CASP9 and chronic kidney disease.